Evaluation of Continuous Subcutaneous Insulin Infusion (CSII) as an Alternative Therapy for Type 1 Diabetes in Paediatric Patients: A Focus on HbA1c Levels.

Type 1 diabetes mellitus (T1DM) is a chronic autoimmune disorder commonly diagnosed in children or teens. This leads to a complete absence of insulin production due to the immune system's targeted destruction of the pancreatic beta cells responsible for insulin synthesis. Effective management of type 1 diabetes necessitates the maintenance of optimal glycemic control to mitigate the risk of acute complications such as hypoglycemia and hyperglycemia, as well as long-term consequences including macrovascular (e.g., cardiovascular disease) and microvascular (e.g., retinopathy and nephropathy) damage. Hemoglobin A1c (HbA1c) serves as the primary biomarker for assessing average blood glucose levels over the past two to three months, hence monitoring long-term glycemic control. This study examines the impact of continuous subcutaneous insulin infusion (CSII) on glycemic control in diabetes care by comparing patient data from before and after the procedure's implementation. Furthermore, to ascertain whether the use of Continuous Subcutaneous Insulin Infusion (CSII) as opposed to Multiple Daily Injections (MDI) diminishes the incidence of severe hypoglycemic episodes in pediatric patients with type 1 diabetes. Samples from fifteen individuals were analyzed, and blood glucose levels were recorded both during and after the transition to Continuous Subcutaneous Insulin Infusion (CSII) and standard insulin therapy. The average glucose levels and variances were analyzed using statistical methods, including Pearson correlation and t-tests. Following the transition to Continuous Subcutaneous Insulin Infusion (CSII), the outcomes demonstrated a significant enhancement in glycemic regulation, characterized by reduced mean glucose levels and diminished variability. These findings suggest that CSII provides.